Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06148272
Other study ID # 18771
Secondary ID J4O-MC-EZHA
Status Recruiting
Phase Phase 1
First received
Last updated
Start date December 7, 2023
Est. completion date December 2024

Study information

Verified date May 2024
Source Eli Lilly and Company
Contact There may be multiple sites in this clinical trial. 1-877-CTLILL
Phone 1-317-615-4559
Email ClinicalTrials.gov@Lilly.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to measure side effects of LY3971297 injection administered under the skin in healthy participants and obese participants with high blood pressure (BP). Blood tests will be performed to check how much LY3971297 gets into the bloodstream and how long it takes the body to eliminate it. This is a 5-part study. The study duration will be approximately 60 days for Part A and approximately 90 days for Parts B, C, D, and E.


Recruitment information / eligibility

Status Recruiting
Enrollment 188
Est. completion date December 2024
Est. primary completion date October 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - For Parts A, B, C, E, Overtly healthy males or females as determined by medical history and physical examination. - For Parts A, B, C, E, have a screening body mass index (BMI) in the range of 18.5 to 35 kg/m2, inclusive, with no significant weight gain or loss in the past 3 months prior to screening. - For Part C, to qualify as Chinese for the purpose of this study, all the participants' biological grandparents must be of exclusive Chinese descent and born in China - For Part Part D, participants with obesity and hypertension must have a stable dose of antihypertensive medications within the past 3 months prior to screening. - For Part D, obesity BMI in the range of 30 to 40 kg/m2, inclusive, with a waist circumference of at least 102 cm for men and at least 89 cm for women. - For Part E, to qualify as a participant of the first-generation Japanese origin, the participant, the participant's biological parents, and all of the participants' biological grandparents must be of exclusive Japanese descent and born in Japan. - Male participants must agree to adhere to contraception restrictions and female participants must be women not of childbearing potential. Exclusion Criteria: - Have a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders - Have known or ongoing psychiatric disorders that, in the opinion of the investigator, increases the risks associated with study participation - Have blood pressure and/or pulse rate constituting a risk as determined by the investigator. - Have a systolic BP of less than 100 mmHg. - Diagnosed with orthostatic hypotension defined as a decrease in systolic blood pressure of equal to or greater than 20 mmHg or a decrease in diastolic blood pressure of equal to or greater than 10 mmHg when compared with BP from the supine position. - For US sites: have donated blood of more than 500 mL within the previous 3 months of screening or intend to donate blood during the course of the study. - For Singapore sites: Have donated blood of more than 450 mL or more in the past 3 months or provided any blood donation within the past 1 month before screening - Consume more than 10 cigarettes per day (or the equivalent) or are unable or unwilling to abstain from nicotine. - Have alcohol intake that exceeds recommended alcohol consumption limits per local regulation, or are unwilling to stop alcohol consumption 24 hours prior to dosing until discharge. - For Part D, has concurrent use or anticipated use of phosphodiesterase 5 inhibitor such as vardenafil, tadalafil, and sildenafil, soluble guanylyl cyclase activators (such as riociguat and vericiguat). - For Part D, has concurrent or anticipated use of long-acting nitrates or NO donors. - For Part D, has concurrent or anticipated use of beta blockers. - For Part D, has current use of more than 3 mechanism of actions for treatment of hypertension.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
LY3971297
Administered SC
Placebo
Administered SC

Locations

Country Name City State
Singapore Lilly Centre for Clinical Pharmacology Singapore
United States CenExel ACT Anaheim California
United States ICON Early Phase Services San Antonio Texas

Sponsors (1)

Lead Sponsor Collaborator
Eli Lilly and Company

Countries where clinical trial is conducted

United States,  Singapore, 

Outcome

Type Measure Description Time frame Safety issue
Primary Part A: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration Part A: A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module Baseline (Day of Exposure) to Day 29 post-dose
Primary Part B, C, D, & E: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration Part B, C, D, & E: A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module Baseline (Day of Exposure) to Day 57 post-dose
Secondary Pharmacokinetics (PK): Area Under the Concentration curve (AUC) of LY3971297 PK: AUC of LY3971297 Predose on day 1 up to 29 days post dose for Part A and predose on day 1 up to 57 days post dose for Part B, C, D, and E
Secondary PK: Maximum Observed Drug Concentration (Cmax) of LY3971297 PK: Cmax of LY3971297 Predose on day 1 up to 29 days post dose for Part A and predose on day 1 up to 57 days post dose for Part B, C, D, and E
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1